Nivolumab Plus Chemotherapy versus Placebo Plus Chemotherapy in Korean Patients with HER2-Negative, Untreated, Unresectable Advanced or Recurrent Gastric or Gastroesophageal Junction Cancer: Subgroup Analysis of a Randomized, Multicenter, Double-Blind Phase 3 Trial (ATTRACTION-4).

Kang YK, Ryu MH, Oh DY, Oh SC, Rha SY, Lee KW, Chung IJ, Oh SY, Sym SJ, Kang WK, Kim JG, Shim BY, Kim IH, Kim JY, Song EK, Lee HJ, Kang SY, Koo DH, Oh SY.

Open source

DOI: 10.4143/crt.2024.913
Published: 2025-07-02
Container: Cancer Res Treat
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.4143/crt.2024.913,
  title = {Nivolumab Plus Chemotherapy versus Placebo Plus Chemotherapy in Korean Patients with HER2-Negative, Untreated, Unresectable Advanced or Recurrent Gastric or Gastroesophageal Junction Cancer: Subgroup Analysis of a Randomized, Multicenter, Double-Blind Phase 3 Trial (ATTRACTION-4).},
  author = {Kang YK and  Ryu MH and  Oh DY and  Oh SC and  Rha SY and  Lee KW and  Chung IJ and  Oh SY and  Sym SJ and  Kang WK and  Kim JG and  Shim BY and  Kim IH and  Kim JY and  Song EK and  Lee HJ and  Kang SY and  Koo DH and  Oh SY.},
  year = {2026},
  journal = {Cancer Res Treat},
  doi = {10.4143/crt.2024.913},
  url = {https://doi.org/10.4143/crt.2024.913}
}

RIS

TY  - JOUR
TI  - Nivolumab Plus Chemotherapy versus Placebo Plus Chemotherapy in Korean Patients with HER2-Negative, Untreated, Unresectable Advanced or Recurrent Gastric or Gastroesophageal Junction Cancer: Subgroup Analysis of a Randomized, Multicenter, Double-Blind Phase 3 Trial (ATTRACTION-4).
AU  - Kang YK
AU  -  Ryu MH
AU  -  Oh DY
AU  -  Oh SC
AU  -  Rha SY
AU  -  Lee KW
AU  -  Chung IJ
AU  -  Oh SY
AU  -  Sym SJ
AU  -  Kang WK
AU  -  Kim JG
AU  -  Shim BY
AU  -  Kim IH
AU  -  Kim JY
AU  -  Song EK
AU  -  Lee HJ
AU  -  Kang SY
AU  -  Koo DH
AU  -  Oh SY.
PY  - 2026
JO  - Cancer Res Treat
DO  - 10.4143/crt.2024.913
UR  - https://doi.org/10.4143/crt.2024.913
ER  -

APA

YK, K., MH, R., DY, O., SC, O., SY, R., KW, L., IJ, C., SY, O., SJ, S., WK, K., JG, K., BY, S., IH, K., JY, K., EK, S., HJ, L., SY, K., DH, K., & SY., O. (2026). Nivolumab Plus Chemotherapy versus Placebo Plus Chemotherapy in Korean Patients with HER2-Negative, Untreated, Unresectable Advanced or Recurrent Gastric or Gastroesophageal Junction Cancer: Subgroup Analysis of a Randomized, Multicenter, Double-Blind Phase 3 Trial (ATTRACTION-4).. Cancer Res Treat. https://doi.org/10.4143/crt.2024.913

Source records

europe-pmc · retrieved 2026-09-27T07:31:13.491Z